DPP-4 inhibitor is expected to strive against SGLT-2 inhibitor in earnest in type 2 diabetes drug market from next month
DPP-4 inhibitor is expected to strive against SGLT-2 inhibitor in earnest in type 2 diabetes drug market from next month. Ministry of Health and Welfare preannounced administrative notice of 'Details about the applicable standard and method of medical care benefit (drug)' which include changes of...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
